Granules India (Mid Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Granules India Limited |
|||
|
Price: ₹592.40 | ||
| 52 Week Low: ₹365.45 52 Week High: ₹721.00 |
|||
| Market Capital: 13,397.06 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Granules India Share Price Target For 2024
- 1.1.1: Granules India Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Granules India Share Price Target For 2025
- 1.2.1: Granules India Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Granules India Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Granules India Brief Company Overview
- 4: Granules India Financial Performance
- 4.0.1: Is Granules India A Good Buy For Long Term?
To predict the Granules India's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Granules India Share Price Target For 2024
The line chart displays the monthly closing prices of Granules India with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Granules India shares in 2024, see the table below.
Granules India Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 631.01 (+6.51%) | Price Action: Jul 2024 High |
| 2024 Target 2 | 622.09 (+5.01%) | Price Action: Aug 2024 Low |
| 2024 Target 1 | 612.15 (+3.33%) | Price Action: 20 Dec 2024 High |
| Current Price | 592.40 | Granules India's share price as of 20 Dec 2024 |
| Stop Loss 1 | 584.75 (-1.30%) | Price Action: 10 Dec 2024 High |
| Stop Loss 2 | 578.8 (-2.30%) | Price Action: 06 Dec 2024 High |
| Stop Loss 3 | 572.55 (-3.36%) | Technical Indicator: MA50 |
Short-Term Technical Outlook
Current Technical Position: Granules India is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹573.66 serves as the nearest technical reference point.
Historical Returns: 3-month: +6.05% | 6-month: +20.53% | 1-year: +46.50%
Granules India Share Price Target For 2025
The line chart displays the monthly closing prices of Granules India with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Granules India shares in 2025, see the table below.
Granules India Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 847.42 (+43.04%) | Price Action: Chart |
| 2025 Target 2 | 831.62 (+40.38%) | Price Action: Chart |
| 2025 Target 1 | 823.39 (+38.99%) | Fibonacci Extension Level 64.90% |
| Current Price | 592.40 | Granules India's share price as of 20 Dec 2024 |
| Stop Loss 1 | 538.9 (-9.04%) | Price Action: 05 Nov 2024 Low |
| Stop Loss 2 | 531.75 (-10.24%) | Price Action: 25 Oct 2024 Low |
| Stop Loss 3 | 522.65 (-11.78%) | Price Action: Nov 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Granules India is currently trading at 63.8% of its 52-week range (₹365.45 - ₹721).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +46.50% | 3-year: +78.09% | 5-year: +390.80%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Granules India Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹592.40 | ||
| 2024 | ₹662.50 | +11.83% | ₹672.44 |
| 2025 | ₹819.31 | +23.67% | ₹831.60 |
| 2026 | ₹976.71 | +19.21% | ₹991.36 |
| 2027 | ₹1,115.07 | +14.17% | ₹1,131.80 |
| 2028 | ₹1,385.63 | +24.26% | ₹1,406.41 |
| 2029 | ₹1,547.88 | +11.71% | ₹1,571.10 |
| 2030 | ₹1,683.31 | +8.75% | ₹1,708.56 |
| 2031 | ₹1,827.30 | +8.55% | ₹1,854.71 |
| 2032 | ₹1,942.11 | +6.28% | ₹2,056.85 |
| 2033 | ₹2,280.59 | +17.43% | ₹2,314.80 |
| 2034 | ₹2,433.26 | +6.69% | ₹2,469.76 |
| 2035 | ₹2,547.32 | +4.69% | ₹2,585.53 |
| 2036 | ₹2,677.89 | +5.13% | ₹2,728.06 |
| 2037 | ₹2,769.15 | +3.41% | ₹2,951.80 |
| 2038 | ₹3,175.54 | +14.68% | ₹3,223.17 |
| 2039 | ₹3,241.38 | +2.07% | ₹3,290.00 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Granules India Brief Company Overview
Granules India Limited: A Renowned Pharmaceutical Company Granules India Limited, established in 1984, is a leading manufacturer and seller of a diverse range of pharmaceutical products. Expertise in APIs and FDs The company specializes in producing Active Pharmaceutical...
Ingredients (APIs) and Finished Dosages (FDs). Its APIs cover various therapeutic categories, including anti-retrovirals, anti-hypertensives, and anti-histamines. Granules India's FDs include tablets, caplets, and press-fit capsules, offered in various formats to cater to specific market needs. Global Presence and Commitment With a global reach spanning India, North America, Europe, and other international markets, Granules India is committed to providing high-quality products and services to its customers worldwide.Granules India Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 13,397.06 Crore | Market valuation of Granules India's shares. |
| Revenue (TTM) | 4,477.84 Crore | Total revenue generated by Granules India over the past twelve months. |
| Net Income (TTM) | +4,871,810,048.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +15.60% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +10.88% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-18.70% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-4.80% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
32.01 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,097.18 Crore | Sum of Granules India's current & long-term financial obligations. |
| Total Cash | 216.71 Crore | Total amount of liquid funds available to Granules India. |
| Beta | 0.21 | Beta is less than 1 indicating that the Granules India's price is less volatile than the market. |
Is Granules India A Good Buy For Long Term?
Granules India (market cap: ₹13,397.06 Crore) shows strong past performance (5-year return: 524.09%), generating ₹4,477.84 Crore in revenue and ₹487.18 Crore in net profit (TTM) with a 10.88% profit margin. However, Q2 2024-25 reveals a concerning -18.7% sequential revenue drop and a -4.8% year-on-year earnings decline. While the ₹216.71 Crore cash balance is positive, the ₹1,097.18 Crore debt needs consideration. Despite impressive long-term growth, the recent negative trends warrant caution. It's an average buy for the long term, requiring further investigation into the causes of revenue decline.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
